Paul Mieyal

Paul Mieyal, Ph.D., CFA is a Managing Director at Outcome Capital with over 20 years of experience in the life sciences industry.12 He specializes in early-stage life sciences investments and operations, focusing on biotechnology, pharmaceutical, medical device, and diagnostic companies.1

Professional Background

• Current Role: Managing Director at Outcome Capital since April 20211
• Previous Positions:
  • Managing Director of Life Sciences Investments at Wexford Capital (2006-2020)1
  • CEO of Nephros, Inc. (2010-2012)1
  • Vice President at Wechsler & Co., Inc. (2000-2006)1

Education and Certifications

• Ph.D. in Pharmacology from New York Medical College1
• Bachelor of Arts in Chemistry and Psychology from Case Western Reserve University1
• Chartered Financial Analyst (CFA)1
• FINRA Registered Securities Representative (Series 79, 7, and 63)12

Expertise

Dr. Mieyal has extensive experience in:

• Public and private board representation
• Venture capital and private equity
• Licensing negotiations
• Mergers and acquisitions (M&A)
• Initial public offerings (IPOs)1

He has served as a director or observer on the boards of numerous life sciences companies, including AZTherapies, Ellipse Technologies, Invuity, and Nephros.2